Twitter | Search | |
Search Refresh
Benlazar S.M Aminé 14h
A great work by the Italian group, To asses outcome of in older patients .
Reply Retweet Like
Raul Cordoba, MD, PhD 14h
THE ELDERLY PROJECT BY ⁦⁩: A PROSPECTIVE COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) OF 1353 ELDERLY PATIENTS WITH DIFFUSE LARGE B‐CELL
Reply Retweet Like
DocWire News Aug 15
-Cell Therapy Shows Activity in Without Measurable Disease - Docwire News
Reply Retweet Like
Isabela G A Pereira Jun 17
Reply Retweet Like
Priyanka Raheja Jun 14
Impact of late relapses on outcomes in patients with DLBCL
Reply Retweet Like
Sanam Loghavi, MD Apr 27
Dr. Shaoying Li presenting the features of
Reply Retweet Like
HMRN UK Dec 1
HMRN are at . Our unique population-based data confirms that the mortality of DLBCL patients who survive 2-years after diagnosis nearly returns to the background rate seen in the general population. Poster #1695
Reply Retweet Like
Toby Eyre Jul 25
Goy et al R-IBR-LEN in R/R MTD not reached ORR 44% CR 28% in 'evaluable' ORR 38% in all pts. ORR 65% non-GCB; 69% in relapsed mPFS 5.5m all pts but non-GCB PFS ⬇️3.9m mDOR 15.9m GI tox fatigue rash myelosupp AE Gd results Why better tolerated than ?
Reply Retweet Like
Graham Collins Jul 29
Tips when giving RCHOP for : - need echo? (>70 or IHD RFs) - need CNS proph? (CNS-IPI 4+ or high risk site) - full dose? (RminiCHOP in >80yr?) - TLS proph to use? (rasburicase v allopurinol) - GCSF proph? (low threshold) - RT after (prior bulk)
Reply Retweet Like
Benlazar S.M Aminé Aug 14
CD47 expression defines efficacy of rituximab with CHOP in Non-Germinal Center B-cell (non-GCB) patients , but not in GCB DLBCL
Reply Retweet Like
Thilo J Zander, MD Jun 19
Dr Carl June describes how to optimize CAR-T cell therapy by giving concomitantly in and maybe patients
Reply Retweet Like
Graham Collins Jun 19
Great abstract by Spina et al. Elderly . - > 1000 pts, pros study - 3 risk gps based on ADL, IADL, CIRS, age - FIT, UNFIT & FRAIL - FRAIL do surprisingly well: almost 50% OS - In FRAIL & UNFIT, ‘curative’ & ‘intermed’ Rx outcomes approx same
Reply Retweet Like
Hasan Faheema May 16
Reason for predilection of adrenal DLBCL's to CNS .
Reply Retweet Like
Michael O'Dwyer Dec 3
CRISPR screening shows critical role for TRAIL and DR5 receptor for mediated killing of
Reply Retweet Like
Marek Trneny Jun 19
-CHOP for 2 studies, 2 designs, 2 populations, 2 different Dg-Tx intervals, 2 different results...
Reply Retweet Like
JIM - Journal of Internal Medicine Feb 28
Impact of intended and relative dose intensity of R‐CHOP in a large, consecutive cohort of elderly Diffuse large B cell () patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.
Reply Retweet Like
Marek Trneny Jun 19
happy and proud to present on the behalf of large number of investigators the impact of TMTV on identification of primary refractory patients in the GOYA study at
Reply Retweet Like
Carsten Nielsen Apr 19
Getting a PET/CT bright and early in Buffalo on Monday morning. This will let the doctors see if my lesions and tumors have grown/shrunk/disappeared and how metabolically active they are 🤞🏼
Reply Retweet Like
Riyue Sunny Bao, PhD Jun 19
Dr. Michael Leukam ⁦⁩ speaking on his ongoing study ‘Genomic correlates of anti-tumor immunity in diffuse large B-cell lymphoma’ super exciting study and progress!!
Reply Retweet Like
Graham Collins Jun 8
Very important study. For patients with DLBCL in remission at 2y (which is when we discharge from follow up), chance of relapse with in next 5y is 9%. Need to educate patients how to detect relapse and offer a rapid way back into the system.
Reply Retweet Like